Table 1.

A summary of clinical trials with isoform-specific isocitrate dehydrogenase inhibitors.

Inhibitor	Target	Cancer	Current Status of Clinical Trials	Identifier at ClinicalTrials.Gov	Company	Reference
AG-120	Mutant IDH1	Cholangiocarcinoma, chondrosarcoma, glioma and advanced solid tumors	Phase I	NCT02073994	Agios Pharmaceuticals Inc./Celgene Corporation	[71,73,85]
		Advanced hematologic malignancies: relapsed or refractory AML, untreated AML, other hematologic malignancies	Phase I	NCT02074839	Agios Pharmaceuticals Inc./Celgene Corporation
		Newly diagnosed AML, untreated AML, AML arising from MDS, AML arising from antecedent hematologic disorder, AML arising after exposure to genotoxic injury	Phase I	NCT02632708	Agios Pharmaceuticals Inc./Celgene Corporation
		Newly diagnosed AML	Phase Ib/II	NCT02677922	Agios Pharmaceuticals Inc./Celgene Corporation
AG-221 (Enasidenib)	Mutant IDH2	Advanced hematologic malignancies	Phase I/II	NCT01915498	Agios Pharmaceuticals Inc./Celgene Corporation	[72,82,83,84,85]
		Advanced solid tumors including glioma, angioimmunoblastic T-cell lymphoma, intrahepatic cholangiocarcinoma chondrosarcoma	Phase I/II	NCT02273739	Agios Pharmaceuticals Inc./Celgene Corporation
		Late-stage AML	Phase III	NCT02577406	Agios Pharmaceuticals Inc./Celgene Corporation
		Newly diagnosed AML, untreated AML, AML arising from MDS, AML arising from AHD, AML arising after exposure to genotoxic injury	Phase I	NCT02632708	Agios Pharmaceuticals Inc./Celgene Corporation
		Newly diagnosed AML	Phase Ib/II	NCT02677922	Agios Pharmaceuticals Inc./Celgene Corporation
AG-881	Mutant IDH1 and IDH2	Advanced hematologic malignancies: AML, MDS	Phase I	NCT02492737	Agios Pharmaceuticals Inc./Celgene Corporation	[67,70]
		Advanced solid tumors: cholangiocarcinoma chondrosarcoma, gliomas	Phase I	NCT02481154	Agios Pharmaceuticals Inc./Celgene Corporation
AGI-6780	Mutant IDH2	AML	-	-	Agios Pharmaceuticals Inc.	[80,81]
AGI-5198	Mutant IDH1	Chondrosarcoma, low-grade WHO glioma	-	-	Xcess Biosciences Inc.	[74,75]
BAY-1436032	Mutant IDH1	Advanced solid tumors, including anaplastic glioma, glioblastoma, intrahepatic cholangiocarcinoma	Phase I	NCT02746081	Bayer	[76]
FT-2102	Mutant IDH1	AML, high-risk MDS	Phase I/Ib	NCT02719574	Forma Therapeutics Inc.	[67]
HMS-101	Mutant IDH1	AML	-	-	Ascenion GmnH	[78]
IDH305	Mutant IDH1	II or III WHO glioma	Phase II	NCT02977689	Novartis AG Pharmaceuticals	[79]
		Low-grade glioma	Phase II	NCT02987010
		AML and advanced solid tumors including cholangiocarcinoma and glioma	Phase I	NCT02381886
		AML	Phase I	NCT02826642